A61P 7 - Drugs for disorders of the blood or the extracellular fluid

Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2001
11/15/2001	WO2001085201A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis
11/15/2001	WO2001085199A1 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A TFPI INHIBITOR
11/15/2001	WO2001085198A1 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII
11/15/2001	WO2001085188A2 Use of echinacea as a hematinic agent
11/15/2001	WO2001085100A2 Vasodilator-thrombolytic fusion proteins and conjugates
11/15/2001	WO2001055172A3 ISOLATED COMPLEX COMPRISING A NNT-1 PROTEIN AND IN ADDITION AT LEAST A CLF-1 PROTEIN AND/OR A sCNTFRα PROTEIN
11/15/2001	WO2001032878A3 A novel polypeptide hormone phosphatonin
11/15/2001	WO2000071507A3 INHIBITORS OF FACTOR Xa
11/15/2001	US20010041802 Glucocorticoid receptor antagonists for treatment of diabetes
11/15/2001	US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/15/2001	US20010041720 2-Amino-N-((1R)-2-((3R)-3-benzyl-3-(N,N',N' -trimethylhydrazinocarbonyl)piperidin-1-yl)-1-(1H-indol-3-ylmethyl)-2 -oxoethyl)-2-methylpropionamide; increasing rate and extent of growth, milk and wool production
11/15/2001	US20010041710 (4R)-1-(4-(4-Fluorophenoxy)benzyl)-2-oxo-imidazolidine-4 -carboxylic acid hydroxyamide, for example; treating various diseases including osteoarthritis, rheumatoid arthritis, cancer, osteoporosis, strokes
11/15/2001	US20010041703 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair
11/15/2001	US20010041681 Therapeutically useful synthetic oligonucleotides
11/15/2001	US20010041184 Silanized stainless steel surface coupled to nucleophilic amine residues then reacted with nitric oxide gas
11/15/2001	DE10113324A1 A combined plant coagulate composition, process for the manufacture thereof and uses thereof
11/15/2001	DE10022925A1 New indole-carboxamide or azepino-indole derivatives and analogs, are poly-ADP ribose polymerase inhibitors useful e.g. for treating neurodegenerative disease, ischemia, epilepsy, tumors, sepsis or diabetes mellitus
11/15/2001	CA2776904A1 A device for forming or increasing the number of undifferentiated cells
11/15/2001	CA2408751A1 2-substituted pregna-1, 3, 5 (10) -triene and chola-1, 3, 5 (10)-triene derivatives and their biological activity
11/15/2001	CA2408297A1 Cancer diagnosis and assays for screening anti-cancer agents
11/15/2001	CA2408213A1 Protein complexes and assays for screening anti-cancer agents
11/15/2001	CA2408156A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001	CA2408002A1 Enzymatic assays for screening anti-cancer agents
11/15/2001	CA2407852A1 Ortho-substituted anthranilic acid amides and their use as medicaments
11/15/2001	CA2407850A1 Cytoskeleton-associated proteins
11/15/2001	CA2407830A1 Amino acid derivatives and their use as medicines
11/15/2001	CA2407817A1 Anthranilamides and their use as pharmaceutical agents
11/15/2001	CA2407712A1 Use of echinacea as a hematinic agent
11/15/2001	CA2406583A1 Pharmaceutical composition comprising a factor viia and a factor xiii
11/14/2001	EP1153014A2 Beta-alanine derivatives
11/14/2001	EP1152755A1 Essential fatty acids in the prevention of cardiovascular events
11/14/2001	EP0832077B1 Improved isoxazoline fibrinogen receptor antagonists
11/14/2001	EP0763037B1 [a]-ANNELATED PYRROLE DERIVATIVES AND PHARMACEUTICAL USE THEREOF
11/14/2001	EP0652900B1 Thrombin inhibitors
11/14/2001	CN1322209A Flavonoids derived from citrus peels as collagen-induced platelet aggregation inhibitor
11/14/2001	CN1322194A Substituted phenyl derivatives, their preparation and use
11/14/2001	CN1322193A Unsaturated hydroximic acid derivatives as PARP inhibitors
11/14/2001	CN1321745A Macrophage inflammatory protein -3, -4 and -1 gamma
11/14/2001	CN1321690A New-type bifunctional hirudin and its preparation method and application
11/14/2001	CN1321639A Substd. heterocyclic compounds, preparing process thereof and pharmaceutical composition contg them
11/14/2001	CN1321634A Substd heterocyclic compounds preparing method thereof and pharmaceutical composition contg. them
11/14/2001	CN1321479A Chinese medicine preparation for curing hematopathy
11/14/2001	CN1321468A Freeze-dried plasma without blood group and its preparation method
11/14/2001	CN1321467A Fresh refrigerated plasma without blood group
11/14/2001	CN1074677C Medicine for treating apoplexy and its preparing process
11/13/2001	US6316502 Administering disulfide derivative of dithiocarbamate compound to bind to iron
11/13/2001	US6316485 1,5-diphenylpyrazole derivatives
11/13/2001	US6316482 Benzamide derivatives having a vasopressin antagonistic activity
11/13/2001	US6316478 IL-8 receptor antagonists
11/13/2001	US6316472 Heterosubstituted pyridine derivatives as PDE 4 inhibitors
11/13/2001	US6316471 Treating inflammatory or autoimmune diseases
11/13/2001	US6316458 Method of enhancing insulin action
11/13/2001	US6316425 Therapeutic agents
11/13/2001	US6316403 Deactivation of factor ix for coagulation inhibition and antiischemic agents
11/13/2001	US6316259 Antisense inhibition of glycogen synthase kinase 3 alpha expression
11/13/2001	US6316258 Inhibiting angiotensin/renin induced generation of transforming growth factor; mix renin with modulator and sample, incubate, evaluate sample for reduced generation of transforming growth factor
11/13/2001	US6316254 Methods for stimulating erythropoiesis using hematopoietic proteins
11/13/2001	US6316226 For use in treatment of hemophilia a
11/13/2001	US6315998 Administering anti-cd40 monoclonal antibody or an antigen binding fragment which is being free of significant agonistic activity and binding to a human cd40 antigen located on surface of a human b cell prevents growth or differentiation
11/13/2001	US6315995 Adding to blood inactive recombinant mutein comprising proteolytically inactive mutein of factor ix or ixa to inhibit clot formation, does not interfere with hemostasis when the blood is administered to a patient
11/13/2001	US6315706 Method for separating cells, especially platelets, and bag assembly therefor
11/13/2001	US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/08/2001	WO2001083775A2 Proteases
11/08/2001	WO2001083725A1 Human coagulation factor vii variants
11/08/2001	WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	WO2001083554A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083547A2 Anti-inflammatory compounds and uses thereof
11/08/2001	WO2001083525A2 Modified peptides, comprising an fc domain, as therapeutic agents
11/08/2001	WO2001083524A2 Rna metabolism proteins
11/08/2001	WO2001083514A2 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001	WO2001083510A1 29 human secreted proteins
11/08/2001	WO2001083454A1 Benzosuberonylpiperidine compounds as analgesics
11/08/2001	WO2001083439A2 Novel $g(y) crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same.
11/08/2001	WO2001083427A1 PPARη MODULATORS
11/08/2001	WO2001083425A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
11/08/2001	WO2001082980A1 A medicinal aerosol formulation
11/08/2001	WO2001082968A1 Cell proliferation inhibitors
11/08/2001	WO2001082953A2 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
11/08/2001	WO2001082952A2 USE OF α-MSH AND EPO FOR PREVENTING OR TREATING ISCHEMIC CONDITIONS
11/08/2001	WO2001082943A2 Subcutaneous administration of coagulation factor vii
11/08/2001	WO2001082940A1 Plant extract of the olea europaea species as no-synthase inhibitor and uses
11/08/2001	WO2001082920A2 Treatment of congestive heart failure with a composition comprising a diuretic agent and a vasopressin antagonist
11/08/2001	WO2001082919A2 Methods of and compounds for inhibiting calpains
11/08/2001	WO2001082896A1 Hemostatic agent, method and carrier for applying a blood clotting agent
11/08/2001	WO2001082874A2 A medicinal aerosol formulation
11/08/2001	WO2001082868A2 A medicinal aerosol formulation
11/08/2001	WO2001082699A1 A gene therapy system and method using alpha-msh and its derivatives
11/08/2001	WO2001044242A9 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
11/08/2001	WO2001039777A8 Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
11/08/2001	WO2001036489A3 Erythropoietin forms with improved properties
11/08/2001	WO2000076556A9 High dose radionuclide complexes for bone marrow suppression
11/08/2001	WO2000069897A3 Modulation of glgf motif (dhr/pdz) containing proteins interaction with cd3n in t lymphocytes
11/08/2001	US20010039414 Sustained release delivery systems for solutes
11/08/2001	US20010039350 Suitable for prophylaxis of diseases involving interleukin-1 beta such as septic shock, leukemia, hepatits, muscular degeneration, HIV infections, or degenerative joint diseases
11/08/2001	US20010038859 Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
11/08/2001	CA2414296A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2414290A1 Anti-inflammatory compounds and uses thereof
11/08/2001	CA2408073A1 Nucleic acids encoding a novel regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001	CA2407965A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	CA2407956A1 Modified peptides as therapeutic agents

1 ... 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 ... 671